Mad Hedge Biotech and Healthcare Letter June 26, 2025 Fiat Lux Featured Trade: (HERE COMES THE ANTI-OZEMPIC) (REGN), (NVO), (LLY)
Category Archives: Biotech Letter
Back in the early 2000s, I remember a dinner with a hedge fund friend who swore Regeneron (REGN) would never be more than a one-trick pony with a laser pointer. That same pony is now gearing up to run a very different race. Regeneron is now dipping its toe into the trillion-calorie battlefield that is […]
Mad Hedge Biotech and Healthcare Letter June 24, 2025 Fiat Lux Featured Trade: (PRESS 1 FOR ENGLISH, PRESS 2 FOR ROBOT SURGERY) (GH), (ILMN), (ISRG), (SYK), (VRTX), (EXAS), (NTRA), (PHG), (TEM)
Let me set the scene. You’re stuck in a doctor’s waiting room that still smells like the Clinton administration, flipping through a Time magazine featuring the rise of the iPhone 6 (because apparently time stopped in medical offices). Then a robot wheels by carrying a tray of someone else’s blood samples. Your doctor, meanwhile, is […]
Mad Hedge Biotech and Healthcare Letter June 17, 2025 Fiat Lux Featured Trade: (THE ART OF WAR, IMMUNOLOGY EDITION) (ABBV), (NVO), (LLY), (JNJ)
Last month, as I pored over pharma earnings with a strong espresso and a stronger sense of deja vu, I was reminded why I swapped the lab coat for a Bloomberg terminal four decades ago. Markets may not speak Latin, but they sure know how to butcher nuance. And AbbVie (ABBV), dear readers, is a […]
Mad Hedge Biotech and Healthcare Letter June 12, 2025 Fiat Lux Featured Trade: (HOW TO SELL ONE MOLECULE TWO WAYS AND MAKE BILLIONS) (NVO), (PFE), (HIMS), (LFMD), (CVS), (LLY)
Did you know Novo Nordisk’s (NVO) Ozempic and Wegovy are basically twins separated at birth? Both contain the same molecule — semaglutide — yet Wegovy costs three times more simply because it moonlights as a weight-loss drug instead of a diabetes treatment. That, my friends, is pharmaceutical sorcery so profitable it would make Merlin jealous. […]
Mad Hedge Biotech and Healthcare Letter June 10, 2025 Fiat Lux Featured Trade: (THIS BIOTECH’S OBITUARY WAS PREMATURE) (AMGN)
Last Tuesday, while stuck in airport security behind a family debating whether insulin syringes count as “liquids,” I had an epiphany about Wall Street’s chronic inability to see past quarterly earnings reports. Here was life-saving biotechnology reduced to a TSA checkbox, while across the terminal, CNBC was breathlessly explaining why Amgen’s (AMGN) “patent cliff” makes […]